To hear about similar clinical trials, please enter your email below
Trial Title:
A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells
NCT ID:
NCT05648188
Condition:
Non Small Cell Lung Cancer
Conditions: Official terms:
Lung Neoplasms
Neoplastic Cells, Circulating
Study type:
Observational
Overall status:
Not yet recruiting
Study design:
Time perspective:
Prospective
Intervention:
Intervention type:
Biological
Intervention name:
Sample
Description:
Sample of whole blood and tissue for ex vivo expression of A2R, CD39, CD73 and P2RX7
Arm group label:
NSCLC patients
Summary:
Early non-small cell lung cancer (NSCLC), treated by surgery or radiotherapy in the case
of inoperability, relapses in almost 50% of cases. Circulating tumour cells (CTCs), which
can be detected before surgery, represent a promising prognostic tool, but the markers
characterising their aggressiveness remain to be determined. The NSCLC microenvironment,
in which purinergic signalling is a key pathway, controls tumour development. Adenosine
derived from the action of CD39 and CD73 ectonucleotidases hydrolysing extracellular ATP,
induces immunosuppression of NSCLC by activating A2R receptors. The expression and
prognostic relevance of A2R, CD39 and CD73 on CTCs is unknown. The objectives are to (i)
compare the expression of A2R and CD39 and CD73 on primary tumour cells and CTCs of
patients operated on for early NSCLC, (ii) correlate these data with molecular
characteristics and clinical response, (iii) determine on lung cancer lines whether
irradiation impacts on the expression of A2R, CD39 and CD73. This work could contribute
to the identification of new theranostic biomarkers.
Criteria for eligibility:
Study pop:
Patients operated for a localized NSCLC (IA-IIB stage) in Nice University Hospital,
Thoracic Surgery service.
Sampling method:
Non-Probability Sample
Criteria:
i) Inclusion criteria:
- Patient of legal age (>18 years), any gender,
- operated on for stage (IA to IIB) non-small cell lung cancer (NSCLC)
ii) Exclusion criteria:
- Patient with any other active cancer.
- Lack of evaluable material.
Gender:
All
Minimum age:
18 Years
Maximum age:
N/A
Healthy volunteers:
No
Locations:
Facility:
Name:
CHU de Nice
Address:
City:
Nice
Zip:
06001
Country:
France
Contact:
Last name:
Jonathan BENZAQUEN, Dr
Phone:
492038052
Phone ext:
+33
Email:
benzaquen.j@chu-nice.fr
Start date:
January 1, 2023
Completion date:
October 30, 2024
Lead sponsor:
Agency:
Centre Hospitalier Universitaire de Nice
Agency class:
Other
Source:
Centre Hospitalier Universitaire de Nice
Record processing date:
ClinicalTrials.gov processed this data on November 12, 2024
Source: ClinicalTrials.gov page:
https://clinicaltrials.gov/ct2/show/NCT05648188
